Vera Gorbounova

6.9k total citations · 2 hit papers
23 papers, 3.2k citations indexed

About

Vera Gorbounova is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Vera Gorbounova has authored 23 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 5 papers in Epidemiology. Recurrent topics in Vera Gorbounova's work include Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Vera Gorbounova is often cited by papers focused on Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Vera Gorbounova collaborates with scholars based in Russia, Germany and United States. Vera Gorbounova's co-authors include Joachim von Pawel, Rodryg Ramlau, Natasha B. Leighl, Petr Zatloukal, Martin Reck, Vera Hirsh, N. Moore, Christian Manegold, J. Mezger and Venice Archer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Vera Gorbounova

23 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

2009 1.2k citations Martin Reck, Joachim von Pawel et al. Journal of Clinical Oncology profile →
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

2003 763 citations Frank V. Fossella, Jose R. Pereira et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vera Gorbounova Russia	13	2.2k	1.8k	617	407	354	23	3.2k
L H Einhorn United States	21	1.5k 0.7×	1.3k 0.7×	666 1.1×	314 0.8×	157 0.4×	31	2.7k
Stephen Shibata United States	28	1.2k 0.5×	601 0.3×	433 0.7×	313 0.8×	226 0.6×	84	2.2k
J. Thaddeus Beck United States	29	2.6k 1.2×	1.3k 0.7×	1.3k 2.0×	226 0.6×	623 1.8×	113	3.7k
Sreenivasa Nattam United States	20	1.9k 0.8×	1.0k 0.6×	760 1.2×	130 0.3×	378 1.1×	42	2.6k
Christian Rothermundt Switzerland	25	1.0k 0.5×	971 0.5×	755 1.2×	150 0.4×	371 1.0×	79	2.3k
Lawrence Einhorn United States	23	1.8k 0.8×	2.2k 1.2×	819 1.3×	360 0.9×	226 0.6×	37	4.2k
Pablo Maroto Spain	27	1.5k 0.7×	1.8k 1.0×	1.3k 2.1×	225 0.6×	763 2.2×	164	3.9k
Halla Nimeiri United States	26	1.2k 0.5×	386 0.2×	311 0.5×	446 1.1×	239 0.7×	84	1.8k
Thomas Gauler Germany	30	1.6k 0.7×	1.7k 0.9×	797 1.3×	216 0.5×	481 1.4×	152	3.1k
Atsuo Takashima Japan	30	1.7k 0.7×	1.5k 0.8×	388 0.6×	218 0.5×	221 0.6×	222	2.9k

Countries citing papers authored by Vera Gorbounova

Since Specialization

Citations

This map shows the geographic impact of Vera Gorbounova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vera Gorbounova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vera Gorbounova more than expected).

Fields of papers citing papers by Vera Gorbounova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vera Gorbounova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vera Gorbounova. The network helps show where Vera Gorbounova may publish in the future.

Co-authorship network of co-authors of Vera Gorbounova

This figure shows the co-authorship network connecting the top 25 collaborators of Vera Gorbounova. A scholar is included among the top collaborators of Vera Gorbounova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vera Gorbounova. Vera Gorbounova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Capdevila, Jaume, Lisa Bodei, Philippa Davies, et al.. (2018). Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms. Neuroendocrinology. 108(1). 18–25. 8 indexed citations

García‐Carbonero, Rocio, Anja Rinke, Juan W. Valle, et al.. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy. Neuroendocrinology. 105(3). 281–294. 82 indexed citations

Pavel, Marianne, Juan W. Valle, Barbro Eriksson, et al.. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology. 105(3). 266–280. 110 indexed citations

Perren, Aurel, Anne Couvelard, Jean‐Yves Scoazec, et al.. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification. Neuroendocrinology. 105(3). 196–200. 165 indexed citations

Gorbounova, Vera, et al.. (2017). Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma. Cancer Chemotherapy and Pharmacology. 80(3). 623–629. 5 indexed citations

Pawel, Joachim von, Vera Gorbounova, Martin Reck, et al.. (2014). DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane–platinum regimen as first-line therapy for metastatic non-small cell lung cancer. Lung Cancer. 85(2). 224–229. 27 indexed citations

Monk, Bradley J., Thomas J. Herzog, Stanley B. Kaye, et al.. (2010). Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. Journal of Clinical Oncology. 28(19). 3107–3114. 291 indexed citations

Reck, Martin, Joachim von Pawel, Petr Zatloukal, et al.. (2007). C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S360–S361. 6 indexed citations

Underhill, Craig, David Goldstein, Vera Gorbounova, et al.. (2007). A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer. Oncology. 73(1-2). 9–20. 16 indexed citations

10.

Eberhardt, Wilfried, Martin Reck, Petr Zatloukal, et al.. (2007). 6518 ORAL Subgroup results from a randomised, double-blind, multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704. European Journal of Cancer Supplements. 5(4). 362–362. 3 indexed citations

11.

Manegold, C., Petr Zatloukal, Rodryg Ramlau, et al.. (2007). 6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). European Journal of Cancer Supplements. 5(4). 357–357. 7 indexed citations

12.

Burges, Alexander, Pauline Wimberger, Carolin Kümper, et al.. (2007). Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study. Clinical Cancer Research. 13(13). 3899–3905. 208 indexed citations

13.

Bennouna, Jaafar, Petr Zatloukal, Rodryg Ramlau, et al.. (2007). 6509 ORAL Management of hypertension (HTN) in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line cisplatin and gemcitabine with bevacizumab or placebo – results from randomised phase III trial BO17704. European Journal of Cancer Supplements. 5(4). 359–359. 5 indexed citations

14.

Belani, Chandra P., Jose R. Pereira, Joachim von Pawel, et al.. (2006). Effect of chemotherapy for advanced non-small cell lung cancer on patients’ quality of life. Lung Cancer. 53(2). 231–239. 48 indexed citations

15.

Leonard, Robert, Joyce O’Shaughnessy, Svetislava J. Vukelja, et al.. (2006). Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?. Annals of Oncology. 17(9). 1379–1385. 41 indexed citations

16.

Gorbounova, Vera, et al.. (2005). Phase II trial of oxaliplatin (OXA) and topotecan (TOP) as a first line treatment for the patients (pts) with advanced ovarian cancer (AOC): Preliminary results of a pilot study. Journal of Clinical Oncology. 23(16_suppl). 5116–5116. 3 indexed citations

17.

Burges, Alexander, Pauline Wimberger, Vera Gorbounova, et al.. (2003). 42 Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab® (anti-CD3 X anti-EpCAM). European Journal of Cancer Supplements. 1(5). S17–S17. 2 indexed citations

18.

Fossella, Frank V., Jose R. Pereira, Joachim von Pawel, et al.. (2003). Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group. Journal of Clinical Oncology. 21(16). 3016–3024. 763 indexed citations breakdown →

19.

Miles, David, J. O’Shaughnessy, Guadalupe Cervantes, et al.. (2001). Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: analysis of post-study therapy.. Breast Cancer Research and Treatment. 69(3). 287–287. 12 indexed citations

20.

Belani, Chandra P., Joachim von Pawel, A Płużańska, et al.. (2000). A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 29(1). 60–60. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact